IO Biotech (IOBT) Competitors $1.43 -0.06 (-4.03%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$1.36 -0.06 (-4.55%) As of 07/7/2025 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IOBT vs. ETON, RZLT, CYRX, ERAS, VIGL, CKPT, TECX, SLDB, ARCT, and MBXShould you be buying IO Biotech stock or one of its competitors? The main competitors of IO Biotech include Eton Pharmaceuticals (ETON), Rezolute (RZLT), CryoPort (CYRX), Erasca (ERAS), Vigil Neuroscience (VIGL), Checkpoint Therapeutics (CKPT), Tectonic Therapeutic (TECX), Solid Biosciences (SLDB), Arcturus Therapeutics (ARCT), and MBX Biosciences (MBX). These companies are all part of the "pharmaceutical products" industry. IO Biotech vs. Its Competitors Eton Pharmaceuticals Rezolute CryoPort Erasca Vigil Neuroscience Checkpoint Therapeutics Tectonic Therapeutic Solid Biosciences Arcturus Therapeutics MBX Biosciences Eton Pharmaceuticals (NASDAQ:ETON) and IO Biotech (NASDAQ:IOBT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations. Do analysts recommend ETON or IOBT? Eton Pharmaceuticals currently has a consensus target price of $29.67, indicating a potential upside of 106.16%. IO Biotech has a consensus target price of $9.33, indicating a potential upside of 552.68%. Given IO Biotech's stronger consensus rating and higher probable upside, analysts plainly believe IO Biotech is more favorable than Eton Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eton Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00IO Biotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Does the media prefer ETON or IOBT? In the previous week, Eton Pharmaceuticals had 2 more articles in the media than IO Biotech. MarketBeat recorded 2 mentions for Eton Pharmaceuticals and 0 mentions for IO Biotech. Eton Pharmaceuticals' average media sentiment score of 0.81 beat IO Biotech's score of 0.00 indicating that Eton Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Eton Pharmaceuticals Positive IO Biotech Neutral Do insiders & institutionals believe in ETON or IOBT? 27.9% of Eton Pharmaceuticals shares are owned by institutional investors. Comparatively, 54.8% of IO Biotech shares are owned by institutional investors. 14.9% of Eton Pharmaceuticals shares are owned by company insiders. Comparatively, 4.8% of IO Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has higher earnings and valuation, ETON or IOBT? Eton Pharmaceuticals has higher revenue and earnings than IO Biotech. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than IO Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEton Pharmaceuticals$39.01M9.89-$3.82M-$0.18-79.94IO BiotechN/AN/A-$95.49M-$1.49-0.96 Is ETON or IOBT more profitable? IO Biotech has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -9.49%. Eton Pharmaceuticals' return on equity of -3.15% beat IO Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Eton Pharmaceuticals-9.49% -3.15% -1.08% IO Biotech N/A -162.55%-125.08% Which has more risk and volatility, ETON or IOBT? Eton Pharmaceuticals has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500. Comparatively, IO Biotech has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500. SummaryEton Pharmaceuticals beats IO Biotech on 10 of the 16 factors compared between the two stocks. Get IO Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for IOBT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IOBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IOBT vs. The Competition Export to ExcelMetricIO BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$98.16M$2.91B$5.52B$9.02BDividend YieldN/A2.44%5.24%4.05%P/E Ratio-0.9620.4427.2220.08Price / SalesN/A190.25381.5993.26Price / CashN/A41.7026.2128.59Price / Book2.017.397.945.55Net Income-$95.49M-$55.04M$3.17B$248.49M7 Day Performance3.62%2.51%1.79%4.87%1 Month Performance-10.63%-0.21%1.27%6.63%1 Year Performance21.19%3.41%33.57%20.38% IO Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IOBTIO Biotech2.6363 of 5 stars$1.43-4.0%$9.33+552.7%+19.2%$98.16MN/A-0.9630Positive NewsETONEton Pharmaceuticals2.7064 of 5 stars$14.25+1.7%$29.67+108.2%+333.4%$375.72M$48.33M-79.1720RZLTRezolute2.2392 of 5 stars$4.46+2.5%$11.83+165.3%+20.6%$372.01MN/A-3.8840Positive NewsHigh Trading VolumeCYRXCryoPort2.9255 of 5 stars$7.46+0.7%$11.00+47.5%+12.5%$371.52M$228.38M-3.191,186News CoverageERASErasca3.0172 of 5 stars$1.27-3.1%$4.57+260.0%-34.6%$371.11MN/A-2.05120VIGLVigil Neuroscience3.3269 of 5 stars$7.95flat$10.80+35.8%+98.3%$371.04MN/A-3.8840CKPTCheckpoint Therapeutics0.4231 of 5 stars$4.26flat$4.33+1.7%N/A$370.71M$41K-2.3210TECXTectonic Therapeutic3.0294 of 5 stars$19.87+0.4%$83.60+320.7%+31.9%$369.72MN/A-2.72120Analyst UpgradeSLDBSolid Biosciences3.1402 of 5 stars$4.87+3.2%$15.10+210.1%-16.4%$365.87M$8.09M-1.63100ARCTArcturus Therapeutics3.727 of 5 stars$13.01-2.4%$53.50+311.2%-37.7%$361.52M$152.31M-5.14180Analyst DowngradeMBXMBX Biosciences3.0646 of 5 stars$11.41+6.1%$37.50+228.7%N/A$359.31MN/A0.0036 Related Companies and Tools Related Companies Eton Pharmaceuticals Competitors Rezolute Competitors CryoPort Competitors Erasca Competitors Vigil Neuroscience Competitors Checkpoint Therapeutics Competitors Tectonic Therapeutic Competitors Solid Biosciences Competitors Arcturus Therapeutics Competitors MBX Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IOBT) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredInstant Cash (in 4 clicks)Since 1973, Wall Street has quietly used a strange little pricing quirk to cash flow billions. Now, for the...Awesomely, LLC | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IO Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IO Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IOBT Stock Alerts